Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q5VVJ2

UPID:
MYSM1_HUMAN

ALTERNATIVE NAMES:
Myb-like, SWIRM and MPN domain-containing protein 1

ALTERNATIVE UPACC:
Q5VVJ2; A8KA54; B3KX65; Q68DD3; Q6AI53; Q7Z3G8; Q96PX3

BACKGROUND:
The protein Deubiquitinase MYSM1, alternatively named Myb-like, SWIRM and MPN domain-containing protein 1, functions as a metalloprotease with deubiquitinase activity. It is essential for regulating hematopoietic stem cell functionality, blood cell production, and immune responses. MYSM1's activities include promoting B-cell response to antigens, repressing innate immunity, preventing autoimmunity, and facilitating the deubiquitination of key immune signaling complexes.

THERAPEUTIC SIGNIFICANCE:
Deubiquitinase MYSM1's involvement in Bone marrow failure syndrome 4 (BMFS4), characterized by hematopoietic defects and developmental aberrations, underscores its therapeutic potential. Targeting MYSM1's regulatory mechanisms could lead to innovative treatments for BMFS4 and enhance our understanding of hematopoietic and immune system disorders, paving the way for novel therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.